Lyme Disease Vaccine Market Overview
lyme disease vaccine market size was valued at USD 304.23 million in 2025 and is poised to grow from USD 331 million in 2026 to USD 426.31 million by 2035, growing at a CAGR of 8.8% during the forecast period (2026-2035).
The Lyme Disease Vaccine Market is entering a more clinically significant development phase as tick exposure expands geographically, veterinary vaccination remains established, and human vaccine research approaches potential regulatory milestones. More than 89,000 human Lyme disease cases were reported in the United States during 2023, while broader healthcare estimates indicate approximately 476,000 people may be diagnosed and treated annually. The commercial landscape currently includes established canine vaccines alongside investigational human prevention programs, creating a market that combines routine veterinary immunization with scientific research and future hospital-based opportunities. Within the supplied product classification, Inactivated Vaccine is estimated to account for approximately 46% of current market activity, Other for about 37%, and Attenuated Vaccine for nearly 17%. The Other category is gaining strategic importance because newer research increasingly employs targeted antigen and recombinant approaches rather than traditional whole-organism strategies. Growing awareness of Borrelia burgdorferi, longer tick seasons, pet ownership, preventive veterinary care, and progress in human clinical research are collectively strengthening long-term market prospects.
The United States remains the most influential national market because Lyme disease incidence is heavily concentrated across the Northeast, Mid-Atlantic, and upper Midwest, while infected tick populations have expanded beyond historically recognized counties. Approximately 476,000 people are estimated to receive a Lyme disease diagnosis and treatment each year in the country, creating a substantial population potentially relevant to future human vaccination strategies. No human Lyme disease vaccine is commercially available in the United States as of 2026, but a multivalent OspA-based candidate completed Phase 3 testing and demonstrated more than 70% efficacy in individuals aged 5 years and older, materially improving the outlook for eventual preventive vaccination. In parallel, canine vaccination remains well established: one leading veterinary Lyme vaccine has been administered to more than 4 million dogs since 2009, while another provides demonstrated immunity for at least 15 months. Hospitals, veterinary channels, and Scientific Research institutions therefore represent distinct but increasingly interconnected demand environments.
Download Free sample to learn more about this report.
Key Findings
- Leading Product Type: Inactivated Vaccine is estimated to hold approximately 46% market share, supported by established canine immunization use, recognized antigen exposure profiles, and veterinary preference for well-characterized preventive formulations in endemic areas.
- Leading Application: Hospital is projected to lead long-term application demand with approximately 48% share as potential human vaccination, clinical evaluation, preventive counseling, and administration increasingly concentrate within organized healthcare settings.
- Leading Region: North America is expected to command approximately 55% of market activity, reflecting high disease incidence, mature veterinary vaccination, strong clinical infrastructure, and concentrated preventive-health awareness across endemic U.S. states.
- Fastest Growing Region: Europe is projected to expand at approximately 9.6% annually as broader geographic recognition of Lyme borreliosis and advancing multivalent human vaccine research stimulate preventive-health investment.
- Technology Trend: Multivalent antigen targeting is reshaping development, with a leading human candidate designed around 6 OspA serotypes and Phase 3 efficacy exceeding 70% among participants aged 5 years and above.
- Market Driver: Rising disease burden remains the strongest growth catalyst, with approximately 476,000 people estimated to be diagnosed and treated for Lyme disease annually in the United States.
- Competitive Landscape: Veterinary vaccine competition increasingly emphasizes broader antigen coverage and longer protection, with a leading recombinant canine formulation demonstrating at least 15 months of immunity following its recommended vaccination series.
- Future Outlook: The market could shift materially toward human preventive vaccination during the forecast period, as recent late-stage clinical development has progressed through Phase 3 testing across participants aged 5 years and older.
Latest Trends
The most important trend influencing the Lyme Disease Vaccine Market is the transition toward precisely targeted, multivalent antigen designs capable of addressing multiple Borrelia strains without relying entirely on conventional whole-organism approaches. A leading human candidate uses 6 OspA serotypes and has completed Phase 3 evaluation in individuals aged 5 years and older, with reported efficacy exceeding 70%. This represents a major technological milestone because the United States has had no commercially available human Lyme vaccine since 2002. Veterinary innovation is following a similar antigen-specific direction. One currently marketed canine recombinant vaccine combines OspA with antigenic components corresponding to 7 OspC types and has demonstrated at least 15 months of immunity. Such formulations are expanding the role of the Other segment, estimated at approximately 37% of current product activity, while encouraging developers to emphasize breadth of protection, immune durability, and reduced unnecessary antigen exposure.
A second trend is the increasing convergence of epidemiological surveillance, vaccination awareness, and seasonal risk management. Lyme disease exposure no longer receives attention only in historically high-incidence localities because infected tick ranges have expanded substantially since 1995. More than 89,000 U.S. cases were formally reported in 2023, compared with much larger annual estimates of approximately 476,000 diagnosed and treated individuals, highlighting the difference between surveillance counts and total healthcare encounters. Veterinary prevention is similarly becoming more structured, with canine vaccination beginning from 8 weeks of age for major commercial products and booster protection extending for at least 12 to 15 months depending on the formulation. These conditions encourage healthcare providers, veterinarians, and Scientific Research organizations to treat Lyme prevention as a recurring seasonal strategy rather than a one-time intervention, supporting more predictable vaccine utilization across high-risk geographic areas.
Market Dynamics
Driver
""Increasing Lyme disease exposure is strengthening demand for preventive vaccination.""
Rising disease exposure is the principal driver of the Lyme Disease Vaccine Market. Lyme disease is the most commonly reported vector-borne disease in several high-incidence U.S. regions, and approximately 476,000 people may be diagnosed and treated annually in the United States. Formal surveillance documented more than 89,000 reported cases during 2023, underscoring the substantial public-health burden even before accounting for patients treated on clinical suspicion. Geographic spread also contributes to concern because the recognized range of Lyme disease has expanded considerably since 1995. As more households participate in hiking, outdoor recreation, gardening, camping, and pet ownership, potential contact with infected ticks rises. This epidemiological environment supports Scientific Research investment today and could create substantial Hospital demand if a human preventive vaccine receives authorization during the 2026-2035 forecast period.
Canine vaccination adds a second durable demand engine because dogs are frequently exposed to tick habitats and may require recurring protection. Major commercial vaccines can be administered to healthy dogs beginning at 8 weeks of age, generally using 2 initial doses followed by periodic revaccination. One established inactivated product provides immunity for at least 1 year and has been administered more than 4 million times since 2009. Another recombinant formulation demonstrates at least 15 months of immunity. In certain unvaccinated canine studies, positive Lyme testing has reached levels as high as 73%, highlighting the potential exposure intensity in endemic environments. As veterinary practices increasingly integrate Lyme protection with tick-control counseling, vaccination becomes part of a broader preventive protocol rather than an isolated service, supporting stable repeat demand.
Restraint
""Scientific complexity and vaccine hesitancy can limit adoption despite rising disease awareness.""
Scientific complexity remains a significant restraint because Lyme disease is associated with biologically diverse Borrelia strains and changing antigen expression during transmission from tick to host. Developers must achieve broad protective responses while maintaining acceptable tolerability across potentially millions of recipients. The challenge is particularly important for human vaccines because no Lyme vaccine has remained commercially available in the United States since 2002. A new candidate may therefore need not only regulatory approval but also strong public confidence, clear eligibility recommendations, and effective communication about benefits and risks. Even with Phase 3 efficacy exceeding 70%, adoption could vary substantially according to geography, age, outdoor exposure, physician recommendation, and vaccination attitudes. This creates a more complex demand curve than routine universal immunization programs involving well-established childhood schedules.
Veterinary vaccination also faces adoption constraints because Lyme vaccination is generally risk-based rather than universally applied to every dog. Owners and veterinarians may consider local tick prevalence, outdoor behavior, preventive medications, prior exposure, and travel patterns before vaccination. Recommended primary series commonly require 2 doses separated by several weeks, potentially lowering completion when owners miss follow-up appointments. One major vaccine uses 2 doses given 2 to 4 weeks apart, while another employs a 2-dose sequence around 3 weeks apart. Although protection can then extend for 12 to 15 months, recurring boosters remain necessary. These requirements create logistical friction compared with single-administration products and may restrict penetration in low-incidence areas even as overall market awareness improves.
Opportunity
""Potential human vaccine availability could substantially broaden the addressable prevention population.""
The clearest long-term opportunity is the possible reintroduction of human Lyme vaccination after more than 20 years without an available U.S. product. A recently completed Phase 3 candidate targets 6 OspA serotypes and demonstrated more than 70% efficacy among participants aged 5 years and older. Regulatory progression could transform the Hospital application segment because prevention would potentially extend beyond veterinary channels and research environments into physician offices, vaccination clinics, integrated healthcare systems, and community immunization programs. North America is especially attractive because approximately 476,000 U.S. patients may be diagnosed and treated for Lyme disease annually. Even if vaccination recommendations initially focus on selected high-risk populations rather than all residents, millions of people living or recreating in endemic counties could become candidates for preventive consultation.
Scientific Research represents another significant opportunity because next-generation prevention is expanding beyond traditional vaccine formats. Research efforts increasingly examine multivalent proteins, recombinant antigen combinations, monoclonal antibodies, and seasonal pre-exposure strategies. In 2025, a human monoclonal antibody technology designed for Lyme pre-exposure prophylaxis was licensed for further clinical development, illustrating how prevention could eventually include both vaccines and complementary biologic approaches. Within the supplied market structure, Scientific Research is estimated to represent approximately 27% of application activity in 2026. Continued trials involving participants aged 5 years and older, coupled with surveillance across North America and Europe, could increase research demand for antigen characterization, immunogenicity testing, strain coverage assessment, diagnostic support, and post-authorization monitoring.
Challenge
""Achieving broad protection across diverse strains while maintaining durable immunity remains difficult.""
One of the market's greatest technical challenges is developing vaccines that remain effective against biologically diverse Borrelia strains encountered across different regions. Human vaccine developers are addressing this problem through multivalent formulations, including a candidate targeting 6 OspA serotypes associated with North American and European Lyme disease. Veterinary products also demonstrate the need for antigen breadth, with one recombinant canine vaccine combining OspA and components representing 7 OspC types. The immune response required to interrupt transmission can vary as bacteria alter outer-surface protein expression between the tick and mammalian host. Consequently, developers must evaluate multiple endpoints rather than simply demonstrating antibody generation, increasing trial complexity and extending the time necessary to establish durable protective performance.
Another challenge involves translating strong clinical data into sustained real-world uptake. Protection may require initial multidose vaccination and later boosters, creating adherence issues for both human and veterinary populations. Existing canine vaccines typically require 2 initial administrations, while protection subsequently lasts approximately 12 to 15 months. For future human vaccination, recommendations will need to define age groups, endemic areas, booster timing, and exposure thresholds. This is especially important because reported U.S. surveillance exceeds 89,000 cases annually, yet broader healthcare estimates approach 476,000 diagnoses and treatments, indicating significant variation in how disease burden is measured. Market participants must therefore communicate risk using accurate, geographically relevant evidence rather than relying on a single national incidence figure.
Download Free sample to learn more about this report.
Segmentation Analysis
By Types
Inactivated Vaccine: Inactivated Vaccine is estimated to hold approximately 46% market share, supported by established veterinary products using killed Borrelia isolates to stimulate protective antibody responses. One widely used canine inactivated vaccine contains 2 inactivated Borrelia burgdorferi isolates and is indicated for dogs from 8 weeks of age. Its primary schedule uses 2 doses of 1 milliliter given 2 to 4 weeks apart, followed by revaccination, while demonstrated immunity lasts at least 1 year. Field safety evaluation has involved more than 600 dogs and reported 99.3% reaction-free administration. Since 2009, more than 4 million doses have been administered, illustrating the maturity of inactivated veterinary prevention. The segment benefits from clinician familiarity and established manufacturing processes, although future human market growth may increasingly favor precisely engineered antigen-based technologies.
Attenuated Vaccine: Attenuated Vaccine represents an estimated 17% market share and remains a comparatively limited segment because live weakened bacterial approaches present greater development, safety, and regulatory complexity for Lyme prevention. The theoretical advantage of attenuated approaches is their potential to generate broad immune stimulation with relatively small antigen quantities, but developers must ensure that reduced virulence remains stable while preventing unintended infection risk. This is particularly challenging when vaccination could target populations beginning at 5 years of age or include individuals with differing immune status. As a result, current late-stage human development has favored non-live antigen platforms, while established veterinary offerings primarily use inactivated or recombinant technologies. The segment's market share is therefore expected to remain below 20% unless improved attenuation technologies demonstrate compelling safety and durable protection during future clinical research.
Other: Other accounts for approximately 37% market share and is the fastest-evolving product category because it encompasses newer targeted approaches within the supplied classification, including recombinant and multivalent antigen technologies. A leading canine recombinant vaccine targets OspA and antigenic components corresponding to 7 OspC types, with immunity established for at least 15 months. In human development, a leading investigational vaccine targets 6 OspA serotypes and has demonstrated Phase 3 efficacy exceeding 70% in individuals aged 5 years and older. These technical advances indicate that the Other category could narrow the gap with Inactivated Vaccine through 2035. Developers increasingly prefer defined antigen structures because they allow greater control over composition, strain coverage, manufacturing consistency, and immune targeting compared with whole-organism formulations.
By Applications
Hospital: Hospital is estimated to represent approximately 48% of long-term application demand, particularly because potential human vaccine authorization would shift Lyme prevention into organized healthcare delivery. Hospitals and affiliated outpatient systems are positioned to identify high-risk patients, assess residence and occupational exposure, provide vaccination counseling, manage scheduled doses, and document adverse events. The opportunity is supported by approximately 476,000 people estimated to be diagnosed and treated for Lyme disease annually in the United States. A human vaccine candidate has already completed Phase 3 testing in individuals aged 5 years and older, suggesting that Hospital demand could expand considerably if regulatory authorization and public-health recommendations follow. The segment may also benefit from electronic-health-record reminders and seasonal preventive programs targeting endemic regions before peak tick activity.
Scientific Research: Scientific Research accounts for approximately 27% of application activity as universities, vaccine developers, contract research organizations, diagnostic laboratories, and epidemiology groups investigate Lyme transmission and immune protection. Research covers multiple areas, including OspA and OspC antigen biology, immune durability, Borrelia strain diversity, clinical efficacy, age-specific responses, tick ecology, and post-vaccination surveillance. Phase 3 human vaccine research has evaluated protection among participants aged 5 years and older, while veterinary challenge studies have examined infection, arthritis, antibody responses, and tissue effects. One canine vaccine study used 30 puppies in a controlled tick-challenge design, while another recombinant vaccine demonstrated 93.7% protection against a defined infection endpoint in a small controlled study. Continued research is essential because vaccine performance must be validated across geographic populations and multiple circulating strains.
Others: Others represents approximately 25% of application demand and includes vaccine utilization and preventive activity outside conventional Hospital and Scientific Research settings within the supplied classification. Veterinary clinics form an especially important part of this segment because canine Lyme vaccination is already commercially established. Major products can be administered beginning at 8 weeks of age, and recommended protection extends from at least 12 months to approximately 15 months depending on formulation. Lyme vaccination is frequently coordinated with tick-control programs and annual wellness visits, giving veterinary practices recurring opportunities to assess geographic and behavioral risk. As pet travel and outdoor activity increase, vaccination demand can extend beyond traditionally endemic states because dogs may be exposed during seasonal travel to regions with greater blacklegged tick prevalence.
Download Free sampleto learn more about this report.
Regional Outlook
North America
North America is estimated to account for approximately 55% of Lyme Disease Vaccine Market activity, making it the leading region. The United States is the primary contributor because more than 89,000 Lyme disease cases were formally reported during 2023 and approximately 476,000 people may be diagnosed and treated each year. The Northeast, Mid-Atlantic, and upper Midwest remain major disease clusters, while the geographic distribution of reported cases has expanded significantly since 1995. The region also has mature companion-animal healthcare infrastructure, established canine Lyme vaccines, and extensive vaccine research capabilities. These conditions create a unique combination of existing veterinary demand and prospective human vaccination opportunities.
North American growth is expected to accelerate if a human vaccine becomes available during the forecast period. A late-stage candidate has completed Phase 3 testing in individuals aged 5 years and older and demonstrated efficacy above 70%, potentially supporting future regulatory applications. Veterinary demand remains substantial in parallel: one commercial vaccine has been administered to more than 4 million dogs since 2009 and provides at least 1 year of immunity. Another recombinant formulation offers at least 15 months of protection. This established preventive culture gives North America an advantage in physician and veterinarian awareness, while existing pharmacy and healthcare networks could support rapid distribution if human vaccination recommendations target endemic populations.
Europe
Europe is estimated to represent approximately 24% of global market activity and is projected to be the fastest-growing region at roughly 9.6% annually through the forecast period. Lyme borreliosis occurs across multiple European countries, with variation in Borrelia species and tick ecology creating demand for broad strain coverage. Human vaccine development is particularly relevant because the leading late-stage candidate is designed to target 6 OspA serotypes associated with both North American and European strains. This cross-regional design expands the prospective addressable population beyond a single national disease environment and strengthens incentives for coordinated clinical and epidemiological research.
European market development is supported by well-established healthcare systems, strong vaccination infrastructure, outdoor recreation, forestry-related occupational exposure, and extensive infectious-disease research. Scientific Research is expected to represent more than 30% of near-term regional activity while human vaccination remains investigational. The region also has an established veterinary pharmaceutical base, including the historical presence of Merial in France and broader companion-animal vaccine distribution networks. If a human product receives authorization, Hospital application share could move beyond 50% in higher-incidence countries because primary care and hospital-linked vaccination systems can integrate geographically targeted preventive recommendations.
Asia-Pacific
Asia-Pacific is estimated to account for approximately 11% of global market activity in 2026. Lyme disease incidence is less concentrated than in North America or parts of Europe, but Borrelia infections and related tick-borne diseases occur across northern and temperate areas of the region. Scientific Research therefore represents an important component, accounting for an estimated 34% of regional demand. Increasing diagnostic capability and awareness of vector-borne disease may support gradual market expansion, particularly in countries with advanced vaccine manufacturing, companion-animal healthcare, and infectious-disease research systems.
Veterinary adoption provides another pathway for regional development as pet ownership and premium preventive care continue to expand in major urban markets. Commercial Lyme vaccination may remain more geographically selective than routine core vaccines because exposure risk differs materially across countries and climates. Even a 5% annual increase in high-risk pet vaccination could strengthen regional demand where veterinary awareness improves. Future human vaccination would likely be targeted initially toward recognized endemic zones rather than broad population programs, making epidemiological mapping and surveillance critical for efficient market development through 2035.
Latin America
Latin America is estimated to represent approximately 6% of Lyme Disease Vaccine Market activity. Lyme disease has a lower documented public-health burden than in North America, and diagnostic uncertainty limits the immediate size of human preventive programs. Consequently, Others and Scientific Research collectively represent approximately 61% of regional activity, while Hospital demand remains comparatively limited. Veterinary prevention could expand among internationally mobile pet owners, breeding operations, and animals traveling to higher-risk destinations. Growing companion-animal healthcare expenditure also supports broader awareness of tick-borne disease prevention.
Regional growth is expected to remain moderate but positive, potentially approaching 6% annually in selected veterinary and research channels. Market expansion depends on improved surveillance, veterinarian education, diagnostic availability, and clearer understanding of Borrelia epidemiology. Because canine vaccines generally begin at 8 weeks of age and require 2 initial doses, veterinary practices can integrate Lyme risk evaluation into puppy vaccination schedules where clinically appropriate. Future human vaccine adoption would depend heavily on confirmed disease burden and public-health recommendations rather than simple replication of North American vaccination strategies.
Middle East & Africa
The Middle East & Africa is estimated to account for approximately 4% of global Lyme Disease Vaccine Market activity. Lyme disease is not a leading vaccine-preventable priority across most countries in the region, where other infectious diseases command greater healthcare attention. Scientific Research and specialized veterinary demand therefore contribute a disproportionate share, together representing approximately 65% of regional activity. International travel, imported animals, research programs, and localized tick exposure create limited but identifiable demand for preventive products and diagnostic expertise.
Growth may reach approximately 5% annually in specialized segments as veterinary infrastructure develops and awareness of tick-borne diseases improves. The region is unlikely to adopt large-scale human Lyme vaccination without stronger epidemiological evidence, but research institutions may participate in broader vector-borne disease monitoring. Veterinary vaccines providing at least 12 months of immunity can be attractive in markets where annual clinic attendance is more practical than frequent preventive interventions. Nevertheless, regional market penetration through 2035 is expected to remain substantially below North America's estimated 55% global share.
List of Top Lyme Disease Vaccine Companies
- Merck & Co., Inc. [U.S.]
- Merial [France]
- Zoetis Inc. [U.S]
Top Two Companies Market Share
Merck & Co., Inc.: Merck is estimated to account for approximately 34% of commercially established activity among the supplied competitive group, supported by its recognized canine Lyme vaccine and extensive veterinary distribution. Its inactivated product uses 2 Borrelia burgdorferi isolates and stimulates borreliacidal responses involving OspA and OspC. The vaccine is recommended for healthy dogs from 8 weeks of age, delivered as 2 initial 1-milliliter doses given 2 to 4 weeks apart, and provides immunity for at least 1 year. Safety evaluation involving more than 600 dogs reported 99.3% reaction-free use, while cumulative administration has exceeded 4 million dogs since 2009. This installed clinical base supports recurring booster demand and strong veterinarian familiarity.
Zoetis Inc.: Zoetis is estimated to represent approximately 30% of commercially established activity among the supplied competitive group, led by its recombinant canine Lyme platform. The company's vaccine uses OspA together with chimeric OspC antigenic material associated with 7 relevant OspC types. It is approved for healthy dogs from 8 weeks of age, with a primary 2-dose schedule approximately 3 weeks apart and a demonstrated immunity duration of at least 15 months. Controlled challenge research showed 93.7% protection against a specified infection endpoint, while all 16 unvaccinated control animals in one study became positive according to the study definition. The technology differentiates Zoetis through targeted recombinant design rather than conventional whole-organism inactivation.
Investment Analysis
Investment in the Lyme Disease Vaccine Market is increasingly directed toward multivalent antigen platforms, clinical validation, manufacturing scalability, surveillance, and companion-animal preventive care. Scientific Research represents approximately 27% of application activity, reflecting continued work on immune mechanisms, strain variability, duration of protection, and age-specific efficacy. Human vaccine development has advanced considerably, with a 6-valent OspA candidate completing Phase 3 assessment and demonstrating efficacy above 70% among individuals aged 5 years and older. This development increases the strategic importance of manufacturing capacity and regulatory readiness because a successful authorization would require scaling from clinical supply to substantially larger commercial volumes. Investors are also evaluating companion diagnostics and epidemiological tools capable of identifying high-risk counties and seasonal vaccination windows.
Veterinary prevention remains an attractive investment area because vaccination already follows repeatable schedules and serves a well-defined population. Established products begin at 8 weeks of age, require 2 initial administrations, and provide at least 12 to 15 months of protection. More than 4 million dogs have received one leading product since 2009, demonstrating sustained demand over more than 15 years. Investment priorities include improved antigen specificity, combination preventive-health strategies, practitioner education, manufacturing consistency, and digital reminders that increase annual booster compliance. Companies able to improve completion of the second primary dose by even 10% could increase the number of fully immunized animals without needing equivalent growth in first-dose acquisition.
New Product Development
New product development is increasingly focused on antigen precision rather than simply increasing the amount of biological material administered. In the Other product segment, recombinant and multivalent technologies are designed to present selected Borrelia targets capable of inducing protection against multiple strains. Zoetis' canine recombinant approach combines OspA with chimeric OspC antigenic content associated with 7 OspC types and has established immunity for at least 15 months. Human development is moving in the same broad direction, with a late-stage candidate targeting 6 OspA serotypes and demonstrating Phase 3 efficacy above 70%. These programs illustrate a technology shift toward products designed around transmission biology and strain diversity rather than traditional single-antigen assumptions.
Duration of immunity is another major development target because tick exposure can span multiple seasons and vary with climate. A 15-month veterinary protection claim offers more scheduling flexibility than a narrowly 12-month interval and can reduce the risk of protection gaps when booster appointments are delayed. Companies are therefore likely to evaluate immune persistence at 12, 15, 18, and potentially longer follow-up intervals. For human vaccines, booster requirements will materially affect market adoption because a program requiring frequent doses could create adherence challenges across millions of potential recipients. Simplifying protection while preserving coverage against 6 or more relevant antigenic types would be a significant competitive advantage.
Five Recent Developments
- February 2024: Zoetis continued expanding clinical education around its recombinant canine Lyme vaccine, emphasizing OspA and 7 OspC-related antigenic targets as veterinarians prepared for seasonal tick exposure and recurring immunization programs exceeding 12 months of protection.
- September 2024: Merck & Co., Inc. strengthened veterinary awareness activities for its established inactivated Lyme vaccine, highlighting field safety data from more than 600 dogs and a 99.3% reaction-free profile for preventive vaccination beginning at 8 weeks of age.
- February 2025: Zoetis updated professional Lyme prevention materials using 2024 parasite-prevalence information, reinforcing the role of its recombinant vaccine with at least 15 months of demonstrated immunity and a recommended 2-dose primary vaccination schedule.
- October 2025: Merck & Co., Inc. continued positioning canine Lyme vaccination alongside broader tick-prevention strategies, supported by cumulative administration exceeding 4 million dogs since 2009 and demonstrated immunity lasting at least 1 year after the recommended vaccination series.
- March 2026: Merck & Co., Inc. expanded its broader canine tick-control portfolio with a once-yearly injectable parasiticide label covering additional tick species for 12 months, strengthening integrated preventive strategies that complement recurring Lyme vaccination in exposed dogs.
Report Coverage
The Lyme Disease Vaccine Market assessment covers the period from 2025 through 2035 and evaluates current epidemiology, vaccine technology, product segmentation, application demand, regional patterns, competitive positioning, investment priorities, and recent industry development. The supplied Product Types are limited to Inactivated Vaccine, Attenuated Vaccine, and Other, with estimated shares of approximately 46%, 17%, and 37% respectively. Applications are restricted to Hospital, Scientific Research, and Others, representing approximately 48%, 27%, and 25% of long-term market demand. Geographic analysis includes North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America leads with approximately 55% market activity, while Europe is projected to record the strongest regional growth at about 9.6% annually as human vaccine development and awareness of Lyme borreliosis advance.
The report evaluates technology trends including inactivated whole-organism approaches, attenuated concepts, recombinant antigens, multivalent formulations, OspA targeting, OspC targeting, immune-duration optimization, and complementary seasonal prevention research. Within the supplied categories, Other is expected to gain competitive importance from its current estimated 37% share because targeted antigen approaches dominate recent high-profile innovation. One veterinary product addresses OspA together with 7 OspC-related antigen types, while a human candidate targets 6 OspA serotypes. These technologies seek to improve strain coverage without depending on a single antigenic configuration, an important consideration because Borrelia biology changes during transmission from tick to mammalian host.
| REPORT COVERAGE | DETAILS |
|---|---|
|
Market Size Value In |
US$ 331 Million in 2026 |
|
Market Size Value By |
US$ 426.31 Million by 2035 |
|
Growth Rate |
CAGR of 8.8 % from 2026 to 2035 |
|
Forecast Period |
2026 to 2035 |
|
Base Year |
2025 |
|
Historical Data Available |
2021-2024 |
|
Regional Scope |
Global |
|
Segments Covered |
Type and Application |
Related Reports
-
What will be the projected value of Lyme Disease Vaccine Market by 2035?
The Lyme Disease Vaccine Market is projected to reach USD 426.31 Million by 2035, expanding at a steady pace during the forecast period. Market growth is supported by rising demand, technological advancements, and increasing adoption across major end-use industries worldwide.
-
What is the expected CAGR of the Lyme Disease Vaccine Market during 2026-2035?
The Lyme Disease Vaccine Market is expected to grow at a CAGR of 8.8% during the forecast period from 2026 to 2035.
-
Which companies are leading the Lyme Disease Vaccine Market?
Key players in the Lyme Disease Vaccine Market market include Merck & Co., Inc. [U.S.], Merial [France], Zoetis Inc. [U.S]
-
How large was the Lyme Disease Vaccine Market in 2025?
The Lyme Disease Vaccine Market was valued at USD 304.23 Million in 2025, reflecting strong demand and continued adoption across major industries.
